Regenxbio (RGNX) Misses Q4 EPS by 28c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall St futures drop as oil spikes after Trump rejects Iran peace proposal
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Oil gains over 3% as US-Iran peace talks in stalemate
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
REGENXBIO Reports Fourth Quarter and Full-Year 2019 Financial Results and Operational Highlights
February 26, 2020 4:05 PM ESTROCKVILLE, Md., Feb. 26, 2020 /PRNewswire/ --
Additional data from RGX-314 Phase I/IIa trial for wet AMD expected in 1H 2020 RGX-314 clinical trials for treatment of wet AMD and diabetic retinopathy expected to advance in 2020 using subretinal and suprachoroidal delivery approaches Additional interim data from RGX-121 Phase I/II trial for MPS II expected in 2020 Plans to expand rare disease pipeline into neuromuscular disorders in 2H 2020 $400 million in cash, cash equivalents and marketable securities as of December 31, 2019 Conference call Wednesday, February 26th at... More